FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.uv.xver-r3.r5
Resource TypeValueSet
IdValueSet-R3-v3-substanceAdminSubstitution-for-R5.json
FHIR VersionR5
Sourcehttp://hl7.org/fhir/uv/xver-r3.r5/0.0.1-snapshot-2/ValueSet-R3-v3-substanceAdminSubstitution-for-R5.html
URLhttp://hl7.org/fhir/3.0/ValueSet/R3-v3-substanceAdminSubstitution-for-R5
Version0.0.1-snapshot-2
Statusactive
Date2025-09-01T22:36:01.551929+10:00
NameR3_v3_substanceAdminSubstitution_for_R5
TitleCross-version VS for R3.v3 Code System substanceAdminSubstitution for use in FHIR R5
Realmuv
Authorityhl7
DescriptionThis cross-version ValueSet represents concepts from http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2016-11-11 for use in FHIR R5. Concepts not present here have direct `equivalent` mappings crossing all versions from R3 to R5.

Resources that use this resource

No resources found


Resources that this resource uses

CodeSystem
substanceAdminSubstitutionv3-substanceAdminSubstitution

Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: ValueSet R3-v3-substanceAdminSubstitution-for-R5

This value set expansion contains 9 concepts.

CodeSystemDisplayDefinition
  BChttp://hl7.org/fhir/v3/substanceAdminSubstitutionbrand composition

Description:

                    Substitution occurred or is permitted between equivalent Brands but not Generics

                    
                       Examples: 
                    

                    
                       Zestril  for Prinivil
                       Coumadin for Jantoven
  Ghttp://hl7.org/fhir/v3/substanceAdminSubstitutiongeneric composition

Description: Substitution occurred or is permitted between equivalent Generics but not Brands

                       Examples: 
                    

                    
                       Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
  EChttp://hl7.org/fhir/v3/substanceAdminSubstitutionequivalent composition

Description:

                    Substitution occurred or is permitted with another product that is a:

                    
                       pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
                       pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration
                    
                    
                       Examples: 
                    

                    
                       
                          Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
                       
                          Pharmaceutical equivalent: Lisonpril for Zestril
  TBhttp://hl7.org/fhir/v3/substanceAdminSubstitutiontherapeutic brand

Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics

                       Examples: 
                    

                    
                       Zantac for Tagamet
  TGhttp://hl7.org/fhir/v3/substanceAdminSubstitutiontherapeutic generic

Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands

                       Examples: 
                    

                    
                       Ranitidine  for cimetidine
  TEhttp://hl7.org/fhir/v3/substanceAdminSubstitutiontherapeutic alternative

Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.

                       Examples: 
                    

                    
                       ranitidine for Tagamet
  Ehttp://hl7.org/fhir/v3/substanceAdminSubstitutionequivalent

Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.

  Fhttp://hl7.org/fhir/v3/substanceAdminSubstitutionformulary

Description: This substitution was performed or is permitted based on formulary guidelines.

  Nhttp://hl7.org/fhir/v3/substanceAdminSubstitutionnone

No substitution occurred or is permitted.


Source1

{
  "resourceType": "ValueSet",
  "id": "R3-v3-substanceAdminSubstitution-for-R5",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm",
      "valueInteger": 0
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
      "valueCode": "fhir"
    },
    {
      "extension": [
        {
          "url": "packageId",
          "valueId": "hl7.fhir.uv.xver-r3.r5"
        },
        {
          "url": "version",
          "valueString": "0.0.1-snapshot-2"
        }
      ],
      "url": "http://hl7.org/fhir/StructureDefinition/package-source"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status",
      "valueCode": "trial-use",
      "_valueCode": {
        "extension": [
          {
            "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-conformance-derivedFrom",
            "valueCanonical": "http://hl7.org/fhir/3.0/ImplementationGuide/hl7.fhir.uv.xver-r3.r5"
          }
        ]
      }
    }
  ],
  "url": "http://hl7.org/fhir/3.0/ValueSet/R3-v3-substanceAdminSubstitution-for-R5",
  "version": "0.0.1-snapshot-2",
  "name": "R3_v3_substanceAdminSubstitution_for_R5",
  "title": "Cross-version VS for R3.v3 Code System substanceAdminSubstitution for use in FHIR R5",
  "status": "active",
  "experimental": false,
  "date": "2025-09-01T22:36:01.551929+10:00",
  "publisher": "FHIR Infrastructure",
  "contact": [
    {
      "name": "FHIR Infrastructure",
      "telecom": [
        {
          "system": "url",
          "value": "http://www.hl7.org/Special/committees/fiwg"
        }
      ]
    }
  ],
  "description": "This cross-version ValueSet represents concepts from http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2016-11-11 for use in FHIR R5. Concepts not present here have direct `equivalent` mappings crossing all versions from R3 to R5.",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
          "code": "001",
          "display": "World"
        }
      ]
    }
  ],
  "compose": {
    "include": [
      {
        "system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
        "version": "2016-11-11",
        "concept": [
          {
            "code": "BC",
            "display": "brand composition"
          },
          {
            "code": "G",
            "display": "generic composition"
          },
          {
            "code": "EC",
            "display": "equivalent composition"
          },
          {
            "code": "TB",
            "display": "therapeutic brand"
          },
          {
            "code": "TG",
            "display": "therapeutic generic"
          },
          {
            "code": "TE",
            "display": "therapeutic alternative"
          },
          {
            "code": "E",
            "display": "equivalent"
          },
          {
            "code": "F",
            "display": "formulary"
          },
          {
            "code": "N",
            "display": "none"
          }
        ]
      }
    ]
  },
  "expansion": {
    "timestamp": "2025-09-01T22:36:01.551914+10:00",
    "contains": [
      {
        "system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
        "version": "2016-11-11",
        "code": "BC",
        "display": "brand composition"
      },
      {
        "system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
        "version": "2016-11-11",
        "code": "G",
        "display": "generic composition"
      },
      {
        "system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
        "version": "2016-11-11",
        "code": "EC",
        "display": "equivalent composition"
      },
      {
        "system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
        "version": "2016-11-11",
        "code": "TB",
        "display": "therapeutic brand"
      },
      {
        "system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
        "version": "2016-11-11",
        "code": "TG",
        "display": "therapeutic generic"
      },
      {
        "system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
        "version": "2016-11-11",
        "code": "TE",
        "display": "therapeutic alternative"
      },
      {
        "system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
        "version": "2016-11-11",
        "code": "E",
        "display": "equivalent"
      },
      {
        "system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
        "version": "2016-11-11",
        "code": "F",
        "display": "formulary"
      },
      {
        "system": "http://hl7.org/fhir/v3/substanceAdminSubstitution",
        "version": "2016-11-11",
        "code": "N",
        "display": "none"
      }
    ]
  }
}